Core Viewpoint - The company faced sales pressure during the "Double Eleven" period primarily due to underperformance in live streaming sales, reflecting both strategic channel adjustments and overall industry competition [1][2] Group 1: Sales Performance - The company's online GMV during the Double Eleven period declined approximately 30% year-on-year, with Tmall GMV down about 20% as the company opted out of aggressive price wars in top-tier live streaming [2] - Douyin GMV saw a significant decrease of around 50%, attributed to weak performance in live streaming, with a more than 50% reduction in the number of collaborations with influencers in October [2] - Despite the overall decline, the self-operated channels and mid-tier influencers showed resilience, indicating a solid brand presence and user loyalty [2] Group 2: Strategic Adjustments - The management is focusing on maintaining price stability and enhancing consumer experience, which is expected to lay a foundation for long-term growth and profit margin stability [2] - The company plans to launch several key new products in 2026, which are anticipated to drive a new growth phase [1][3] - The company has been approved to repurchase up to 104 million shares, representing 10% of its total share capital, reflecting confidence in long-term development [1] Group 3: Product Development - The company is actively cultivating a second product tier to optimize its product structure, with expectations for significant revenue growth from new products [3] - In 2026, the company will introduce four major new products across various series, aiming to reduce reliance on single blockbuster products and enhance brand resilience [3] - The medical beauty product line is set to expand, with the first injectable recombinant collagen product approved and planned for rapid market penetration in 2026 [3] Group 4: Financial Outlook - The company has adjusted its revenue growth forecasts for 2025 and 2026 to -3.5% and 13.6%, respectively, reflecting short-term pressures [3] - The target price has been revised to HKD 53.89, maintaining a "Buy" rating based on a DCF model [3]

Core Viewpoint - The report from 招银国际 indicates a downward adjustment of the target price for 巨子生物 (02367) from HKD 58.35 to HKD 53.89, a decrease of 8%, while maintaining a "Buy" rating [1] Group 1: Financial Forecasts - The revenue growth forecast for the company for the years 2025/26 has been revised down to -3.5% and 13.6% respectively [1] - The sales performance during the "Double Eleven" shopping festival was under pressure, primarily due to the underperformance of 达播 [1] Group 2: Strategic Adjustments - The company is actively adjusting its channel strategy, which reflects the overall competitive pressure in the industry [1] - Management is maintaining strategic consistency amidst industry changes, focusing on price maintenance and consumer experience, while increasing the proportion of self-broadcast channels to lay a foundation for long-term growth [1] Group 3: Future Growth Prospects - The company plans to launch several key new products next year to drive a new round of growth [1] - The company has been approved to repurchase up to 104 million shares, accounting for 10% of the total share capital, demonstrating confidence in long-term development [1] - Despite short-term challenges for 可复美 due to declining traffic benefits and intensified competition, the steady growth of 可丽金 and the commercialization of medical beauty products in 2026 may offset the risks associated with the slowdown of 可复美 [1] - The company is expected to rely on a dual-drive strategy of "skincare + medical beauty" to return to a growth trajectory by 2027 [1]

Core Viewpoint - 招银国际 has downgraded the target price for 巨子生物 (02367) by 8% from HKD 58.35 to HKD 53.89 while maintaining a "Buy" rating due to short-term pressures on 可复美's sales performance [1] Group 1: Financial Forecasts - The revenue growth forecast for the company for 2025/26 has been adjusted to -3.5% and 13.6% [1] - The sales during the "Double Eleven" period were under pressure, primarily due to underperformance in 达播's sales [1] Group 2: Strategic Adjustments - The company is actively adjusting its channel strategy, reflecting overall competitive pressures in the industry [1] - Management is maintaining strategic focus amidst industry changes, aiming to protect pricing and consumer experience while increasing the proportion of self-broadcast channels [1] Group 3: Future Growth Prospects - The company plans to launch several key new products next year to drive a new growth phase [1] - The company has been approved to repurchase up to 104 million shares, representing 10% of its total share capital, demonstrating confidence in long-term development [1] Group 4: Risk Mitigation - Short-term growth for 可复美 is expected to slow due to the decline in traffic benefits and intensified competition [1] - However, the steady growth of 可丽金 and the commercialization of medical beauty products in 2026 may offset the risks associated with the slowdown of 可复美 [1] - The company is projected to return to a growth trajectory by 2027, driven by a dual engine of "skincare + medical beauty" [1]

Investment Rating - The report maintains a "Buy" rating for the company with a target price of HKD 53.89, down from a previous target of HKD 58.35, indicating a potential upside of 35.7% from the current price of HKD 39.70 [2][6]. Core Insights - The company's short-term performance is under pressure due to disappointing sales during the "Double Eleven" shopping festival, primarily attributed to the underperformance of the "Dabo" sales channel. This reflects both strategic channel adjustments by the company and overall competitive pressures in the industry [6]. - Management remains committed to maintaining pricing stability and enhancing consumer experience, which is expected to lay a foundation for long-term growth. The company plans to launch several key new products next year to drive a new growth cycle [6]. - The company has been approved to repurchase up to 104 million shares, representing 10% of its total share capital, demonstrating confidence in its long-term development [6]. Financial Summary - For FY23A, the company reported sales revenue of RMB 3,524 million, with a year-on-year growth of 49.0%. Projections for FY25E and FY26E show expected revenues of RMB 5,347 million and RMB 6,075 million, respectively, with growth rates of -3.5% and 13.6% [2][11]. - The net profit attributable to shareholders for FY23A was RMB 1,452 million, reflecting a year-on-year increase of 44.9%. The forecast for FY25E and FY26E is RMB 1,903 million and RMB 2,126 million, with growth rates of -7.7% and 11.7% [2][11]. - The company's price-to-earnings (P/E) ratio is projected to be 24.0 for FY23A, decreasing to 15.2 by FY27E, indicating a potential increase in valuation as earnings grow [2][11]. Sales Performance - During the "Double Eleven" event, the company's online GMV for "Kefumei" declined approximately 30% year-on-year, with Tmall GMV down about 20% due to the company's decision to avoid aggressive price wars. However, the self-operated and mid-tier influencer channels showed resilience [6]. - The "Keli Jin" brand experienced double-digit growth in online GMV during the same period, particularly strong in the Douyin channel, indicating a successful strategy in diversifying sales channels [6]. Product Strategy - The company is actively cultivating a second tier of products to optimize its product structure, with expectations for significant revenue growth from new product launches in 2025 and 2026 [6]. - The medical beauty product line is set to expand, with the first injectable recombinant collagen product approved and plans for rapid terminal coverage expansion in 2026, which is anticipated to become a significant growth driver with higher profit margins than cosmetics [6].

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年11月30日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 巨子生物控股有限公司 呈交日期: 2025年12月3日 本月底法定/註冊股本總額： USD 50,000 FF301 第 1 頁 共 10 頁 v 1.1.1 FF301 II. 已發行股份及/或庫存股份變動 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 02367 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 5,000,000,000 | USD | | 0.00001 | USD | | 50,000 | | 增加 / 減少 (-) | | | | | | | USD | | ...

每经AI快讯，巨子生物(02367.HK)昨日受回购消息刺激一度涨逾12%，今日股价回落逾4%，截至发稿 跌3.38%，报38.36港元，成交额4.28亿港元。 （文章来源：每日经济新闻） ...

Core Viewpoint - The stock of Giant Bio (02367) experienced a significant increase of over 12% following a share buyback announcement, but subsequently fell by over 4% [1] Group 1: Share Buyback Announcement - Giant Bio announced plans to exercise its share buyback authorization, allowing the company to repurchase up to 103.6 million shares, which represents 10% of its issued shares excluding treasury shares [1] Group 2: Sales Performance - According to a report from Bank of America Securities, sales for the Co-Beauty brand during the Double Eleven shopping festival were under pressure, with sales on Tmall and Douyin declining by 20% and 50% year-on-year, respectively [1] - In contrast, the Co-Li Jin brand achieved positive growth during the same period [1] Group 3: Earnings Guidance - Management has revised down its earnings guidance for the year, expecting revenue to remain flat or slightly decline year-on-year, and has lowered its net profit forecast to a mid-to-high single-digit percentage decline year-on-year [1]

Core Viewpoint - The stock of Giant Bio (02367) experienced a significant increase of over 12% due to a share buyback announcement, but subsequently fell by over 4% [1] Group 1: Share Buyback Announcement - Giant Bio announced plans to exercise its share buyback authorization, allowing the company to repurchase up to 103.6 million shares, which represents 10% of the issued shares excluding treasury shares [1] Group 2: Sales Performance - According to a report from Bank of America Securities, sales for the Co-Beauty brand during the Double Eleven shopping festival were under pressure, with sales on Tmall and Douyin declining by 20% and 50% year-on-year, respectively [1] - In contrast, the Co-Li Jin brand achieved positive growth during the same period [1] Group 3: Earnings Guidance - Management has revised down the earnings guidance for the year, expecting revenue to remain flat or slightly decline year-on-year, and has lowered the net profit forecast to a year-on-year decline in the mid to high single digits [1]

Core Viewpoint - Bank of America Securities has downgraded the revenue forecasts for Giant Bio (02367) for 2025 to 2027 by 21%, 24%, and 25% respectively, and has also reduced net profit forecasts by 21%, 24%, and 24% respectively, while lowering the target price from HKD 68.3 to HKD 55.5, but maintains a "Buy" rating due to the potential of newly approved injectable aesthetic products to drive growth next year [1] Revenue and Profit Forecasts - Revenue forecasts for Giant Bio have been reduced by 21%, 24%, and 25% for the years 2025, 2026, and 2027 respectively [1] - Net profit forecasts have also been adjusted downwards by 21%, 24%, and 24% for the same years [1] Target Price Adjustment - The target price for Giant Bio has been decreased from HKD 68.3 to HKD 55.5 [1] Sales Performance - During the Double Eleven shopping festival, sales for the Comfy brand were under pressure, with a year-on-year decline of 20% on Tmall and 50% on Douyin [1] - In contrast, the Collgene brand achieved positive growth during the same period [1] Management Guidance - Management has lowered the performance guidance for the current year, expecting revenue to be flat or slightly down year-on-year [1] - The net profit forecast has been adjusted to reflect a year-on-year decline in the mid to high single digits [1]

Core Viewpoint - Bank of America Securities has downgraded the revenue forecasts for Giant Bio (02367) for 2025 to 2027 by 21%, 24%, and 25% respectively, and has also reduced net profit forecasts by 21%, 24%, and 24%. The target price has been lowered from HKD 68.3 to HKD 55.5, but the "Buy" rating is maintained due to expectations that newly approved injectable aesthetic products will drive growth next year [1] Group 1 - Giant Bio's sales during the Double Eleven shopping festival were under pressure, with management reporting a year-on-year sales decline of 20% on Tmall and 50% on Douyin for the Comfy brand [1] - In contrast, the Collgene brand achieved positive growth during the same period [1] - Management has lowered the performance guidance for this year, expecting revenue to be flat or slightly down year-on-year, and has adjusted net profit forecasts to reflect a mid to high single-digit decline [1]